PDF herunterladen
CC BY-NC-ND 4.0 · South Asian J Cancer 2019; 08(03): 149
DOI: 10.4103/sajc.sajc_400_18
Letter to the Editor

Severe hypoglycemia with trastuzumab: An unseen adverse event

B. P. Amrith
Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
,
Parveen Jain
Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
,
Krushna A. Chaudhari
Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
,
Mansi Sharma
Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
,
Ullas Batra
Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
› Institutsangaben Financial support and sponsorship Nil.
› Weitere Informationen
Auch verfügbar auf
  als PDF herunterladen Lizenzen und Reprints


Publikationsverlauf

Artikel online veröffentlicht:
21. Dezember 2020

© 2019. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Hudis CA. Trastuzumab – Mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51.
  • 2 FDA Label-Trastuzumab. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/trasgen092598lb.pdf. [Last accessed on 2018 Nov 15].
  • 3 Herceptin and Hypoglycemia – From FDA Reports, eHealthME; November, 2018. Available from: https://www.ehealthme.com/ds/herceptin/hypoglycemia. [Last accessed on 2018 Nov 15].